drugset / Trial / NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Timeline
- Start
- 2022-08-19
- Primary completion
- 2027-07
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP1001-A | Antisense oligonucleotide | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |